Article
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
BMC cancer - 1 Apr 2013
Guedes Joana G, Veiga Isabel, Rocha Patrícia, Pinto Pedro, Pinto Carla, Pinheiro Manuela, Peixoto Ana, Fragoso Maria, Raimundo Ana, Ferreira Paula, Machado Manuela, Sousa Nuno, Lopes Paula, Araújo António, Macedo Joana, Alves Fernando, Coutinho Camila, Henrique Rui, Santos Lúcio L, Teixeira Manuel R
Abstract excerpt
BACKGROUND: KRAS is an EGFR effector in the RAS/RAF/ERK cascade that is mutated in about 40% of metastatic colorectal cancer (mCRC). Activating mutations in codons 12 and 13 of the KRAS gene are the only established negative predictors of response to anti-EGFR therapy and patients whose tumors harbor such mutations are not candidates for therapy. However, 40 to 60% of wild-type cases do not respond to anti-EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.